Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2005 1
2006 2
2007 2
2008 2
2010 2
2011 1
2012 1
2013 1
2014 2
2015 3
2016 5
2017 2
2021 1
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
[Central nervous system relapse in diffuse large B cell lymphoma: Risk factors].
Sancho JM, Ribera JM; Working Group on Diagnosis, Prevention and Treatment of CNS Infiltration in Patients with DLBCL. Sancho JM, et al. Med Clin (Barc). 2016 Jan 15;146(2):74-80. doi: 10.1016/j.medcli.2014.12.025. Epub 2015 Mar 24. Med Clin (Barc). 2016. PMID: 25817451 Review. Spanish.
SEGHI Study: Defining the Best Surveillance Strategy in Hodgkin Lymphoma after First-Line Treatment.
Bastos Oreiro M, Martín R, Gomez P, López Muñoz N, Rodriguez A, Liébana M, Navarro B, Sánchez-González B, Marí P, Pérez de Oteiza J, Gutiérrez A, Bento L, Domingo Doménech E, Vidal MJ, Del Campo R, Pérez Ceballos E, Infante M, Roldán A, García Belmonte D, Santero M, Sureda A, Sanz RG, On Behalf Of The Geltamo Group. Bastos Oreiro M, et al. Among authors: perez ceballos e. Cancers (Basel). 2021 May 17;13(10):2412. doi: 10.3390/cancers13102412. Cancers (Basel). 2021. PMID: 34067616 Free PMC article.
IBRORS-MCL study: a Spanish retrospective and observational study of relapsed/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice.
Sancho JM, Marín-Niebla A, Fernández S, Capote FJ, Cañigral C, Grande C, Donato E, Zeberio I, Puerta JM, Rivas A, Pérez-Ceballos E, Vale A, Martín García-Sancho A, Salar A, González-Barca E, Teruel A, Pastoriza C, Conde-Royo D, Sánchez-García J, Barrenetxea C, Arranz R, Hernández-Rivas JÁ, Ramírez MJ, Jiménez A, Rubio-Azpeitia E. Sancho JM, et al. Among authors: perez ceballos e. Int J Hematol. 2022 Sep;116(3):381-392. doi: 10.1007/s12185-022-03367-z. Epub 2022 May 13. Int J Hematol. 2022. PMID: 35551632 Free PMC article.
Accuracy and prognostic impact of FDG PET/CT and biopsy in bone marrow assessment of follicular lymphoma at diagnosis: A Nation-Wide cohort study.
Ródenas-Quiñonero I, Chen-Liang T, Martín-Santos T, Salar A, Fernández-González M, Celades C, Navarro JT, Martínez-Garcia AB, Andreu R, Balaguer A, Martin García-Sancho A, Baile M, López-Jiménez J, Marquet-Palomanes J, Teruel AI, Terol MJ, Benet C, Frutos L, Navarro JL, Uña J, Suarez M, Cortes M, Contreras J, Ruiz C, Tamayo P, Mucientes J, Sopena-Novales P, Reguilón-Gallego L, Sánchez-Blanco JJ, Pérez-Ceballos E, Jerez A, Ortuño FJ. Ródenas-Quiñonero I, et al. Among authors: perez ceballos e. Cancer Med. 2023 Mar;12(6):6536-6546. doi: 10.1002/cam4.5424. Epub 2022 Nov 13. Cancer Med. 2023. PMID: 36373169 Free PMC article.
Association of polymorphisms in TRAIL1 and TRAILR1 genes with susceptibility to lymphomas.
Heredia-Galvez B, Ruiz-Cosano J, Torres-Moreno D, Español I, Morales-Lara MJ, Pérez-Ceballos E, González-Conejero R, Gutiérrez-Cívicos R, Vicente V, Pérez-Guillermo M, Conesa-Zamora P. Heredia-Galvez B, et al. Among authors: perez ceballos e. Ann Hematol. 2014 Feb;93(2):243-7. doi: 10.1007/s00277-013-1864-4. Ann Hematol. 2014. PMID: 23959437 Clinical Trial.
Recommendations on the clinical use of bendamustine in lymphoproliferative syndromes and multiple myeloma.
Peñalver FJ, Delgado J, Loscertales J, Sastre JL, Peña A, Olave MT, Osorio S, de la Fuente A, Salar A, Grande C, Pérez Ceballos E, Debén G, Echeveste A, Casado F, de la Rubia J, Lahuerta JJ, Mateos MV. Peñalver FJ, et al. Among authors: perez ceballos e. Eur J Haematol. 2016 May;96(5):532-40. doi: 10.1111/ejh.12633. Epub 2015 Aug 9. Eur J Haematol. 2016. PMID: 26179864
A polymorphism in FASL is associated with rituximab response in follicular lymphoma patients.
Gutiérrez-Cívicos R, Hurtado AM, Torres-Moreno D, Sanchez-Blanco JJ, Español I, Consuegra-Sánchez L, Perez-Ceballos E, Gutiérrez-Meca MD, Jerez A, Conesa-Zamora P. Gutiérrez-Cívicos R, et al. Among authors: perez ceballos e. Am J Hematol. 2016 Jun;91(6):E305-7. doi: 10.1002/ajh.24354. Epub 2016 Apr 24. Am J Hematol. 2016. PMID: 26950187 Free article. No abstract available.
Rituximab response in follicular lymphoma is associated with the rs20575 polymorphism in TRAILR1 extrinsic apoptosis trigger.
Gutiérrez-Cívicos R, Hurtado AM, Torres-Moreno D, Sanchez-Blanco JJ, Español I, Consuegra-Sánchez L, Perez-Ceballos E, Gutiérrez-Meca MD, Jerez A, Conesa-Zamora P. Gutiérrez-Cívicos R, et al. Among authors: perez ceballos e. Pharmacogenet Genomics. 2017 Feb;27(2):70-77. doi: 10.1097/FPC.0000000000000262. Pharmacogenet Genomics. 2017. PMID: 27977511
26 results